<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955459</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-5133-101/102</org_study_id>
    <secondary_id>DMID 16-0014</secondary_id>
    <secondary_id>272201300019C-3-0-1</secondary_id>
    <nct_id>NCT02955459</nct_id>
  </id_info>
  <brief_title>VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers</brief_title>
  <official_title>VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VenatoRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>VenatoRx Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and
      pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion
      in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2
      subjects will receive VNRX-5133 for 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events; assessed by patient reporting, physical exams, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.</measure>
    <time_frame>Part 1: 8 days. Part 2: 17 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>VNRX-5133</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-5133</intervention_name>
    <arm_group_label>VNRX-5133</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults

          -  Males or non-pregnant, non-lactating females

          -  Body Mass Index (BMI) between 18.5 - 32.0, inclusive.

          -  Suitable veins for cannulation

        Exclusion Criteria:

          -  Employee of site or the sponsor

          -  Any disease that poses an unacceptable risk to participants

          -  Abnormal ECG

          -  Abnormal labs

          -  Abnormal vital signs

          -  Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine,
             autoimmune, hematologic, neoplastic, or neurological disorder

          -  Positive serology for hepatitis B surface antigen, hepatitis C antibody, or human
             immunodeficiency virus (HIV) type 1

          -  Current smokers or history of smoking within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PRAHS</last_name>
    <phone>913-210-5588</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PRAHS</last_name>
      <phone>913-210-5588</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 9, 2016</lastchanged_date>
  <firstreceived_date>November 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
